



L i f e
S c i e n c e s 
H e a l t h

**Public-private partnership, innovation and
collaboration in Life Sciences & Health (LSH)**

**Indo-Dutch workshop on Life Sciences & Health
Trivandrum, India, 21-22 January 2010**

**Menno Horning, MSc, MBA
Head of Unit Life Sciences**

NL Innovation, ministry of Economic Affairs, The Netherlands



The Dutch government has listed “Health” as one of the main themes for innovation

Top-down selection
by government

Themes

- Health
- Climate
- Education
- Enabling Technology
-



Existing PPP

Top Institutes

- BioMedical Materials (BMM)
- Top Institute Pharma (TIP)
- Center for Translational Molecular Medicine (CTMM)

Other Programs

- TeRM
- Parelsnoer
- IT in de zorg



Bottom-up initiatives
from sector



Public Private Partnership - Important model for Open Innovation

**Open Innovation:
from "do it yourself" to "do it together"**


Innovation model for PPP:

- A PPP is a partnership between the private sector, academia/knowledge institutes and the government
- A PPP is flexible and interdisciplinary and stimulates innovation in a field that will give a future competitive advantage
- A PPP is aimed at long-term projects and programs of global top-quality and are often pre-competitive
- The program is jointly funded by the partners



In addition to all benefits for the participants, the multiplier

Contribution to the funding of the research program



Industry, academia, and government jointly contribute to the total funding in a 1 : 1 : 2 ratio

Government
In cash



Health-related life sciences: important sector in the Dutch economy

Drugs

– 430 companies; EUR 12 bn revenues; 37,000 FTE

Diagnostics

– 390 companies; EUR 2.7 bn revenues; 12,000 FTE

Biomedical Engineering and Devices

– 75 companies; EUR 0.4 bn revenues; 2,200 employees

Other


– 40 companies, ≈ EUR 0.8 bn revenues

Health-related life sciences: 935 companies = >150 highly innovative
EUR 15.9 bn output (3% of GDP); 54,600 FTE






Programmatic setup by science, government & industry LSH has an integrated three pillar 'Build – Bundle – Benefit' strategy





Bundle: Public-Private Partnerships focus on diagnosis, drugs and devices with a strong disease focus





Improving innovation climate means overcoming three challenges: 3 LSH action lines



Action line 1

Innovation Credit
€ 25 mln. in 2008
€ 40 mln. in 2009
€ 50 mln. in 2010
pm in 2011

Action line 2


Cooperative projects
€ 5 mln. per annum
Eurotransbio
EuroNanoMed
Bilateral India - NL

Action line 3

Various activities to improve climate
EUR 2.5 per annum



The investment gap is a major hurdle to valorization (action line 1)





International collaboration in LSH for SMEs (action line 2)

- **Hightech SME is focus, but research institutes may partner in the project**
- **Innovation projects (= applied research & (clinical) development**
- **Collaboration with Indian companies & research institutes**
- **Focus on medical drugs, diagnostics, devices & regenerative medicine**
- **Maximum contribution per project at Dutch side € 750.000**
- **Subsidy 45% for research projects and 35 % for development projects**
- **Open call during a specified period t.b.d. after this workshop**
- **Budget for 2010 to be fixed ASAP after this workshop.**



Generic working scheme International Innovation

- **Open for NL collaboration with international in emerging markets**
- **Applicable for India, but also for partners from other countries**
- **Broad focus, not only life sciences**
- **Maximum € 500.000 per project at Dutch side**
- **Also applicable for non SME**
- **Procedure call for tender (deadline 31 June 2010)**
- **Subsidy research projects 35% (+ 10% for SME) and 50% for research institutes; development projects 25% (+10% for SME)**
- **Budget 6 mln.**
-



Thank you!

Discussion & questions.

More information on LSH program:

www.lifesciences.nl